Journal of Drug Discovery and Health Sciences, 2024;1(2):105-112 e-ISSN- 3048-8842

WWW.JDDHS.COM

Journal of Drug Discovery and Health Sciences

journal home page : https://jddhs.com/index.php/jddhs/index

Review Article

Advances in Transdermal Drug Delivery Systems: From Patches to Microneedles

Alfisha Khan[1], Pragati Mishra[2], Deepika Gupta[2*], Poonam Kumari[3]

[1]Department of Pharmaceutics, Jahangirabad Institute of Technology, Faculty of Pharmacy, Barabanki, Uttar Pradesh, India.
[2]Department of Pharmaceutics, Maharishi School of Pharmaceutical Sciences, Maharishi University of Information Technology, Lucknow, Uttar Pradesh, India.
[3]Department of Pharmaceutics, Rajarshi Rananjay Sinh College of Pharmacy, Amethi, Uttar Pradesh, India.

ARTICLE INFO

Article history:
Received: 04 July, 2024
Revised: 20 July, 2024
Accepted: 10 August, 2024
Published: 28 August, 2024

Keywords:
TDDS, Microneedle, Micro-molding, Photolithography, 3D printing, Skin Impermeability.

DOI:
10.21590/jddhs.01.02.06

ABSTRACT

Microneedle technology has emerged as a groundbreaking innovation in transdermal drug delivery systems (TDDS), offering a less invasive method to administer drugs through the skin. These micron-sized needles penetrate the stratum corneum, the outermost layer of the skin, to deliver therapeutic agents ranging from vaccines to insulin and biologics. The four main types of microneedles—solid, coated, dissolvable, and hollow each serve unique purposes in optimizing drug delivery efficiency and patient comfort.

Solid microneedles are typically made of metals like stainless steel and titanium, offering mechanical strength for precise skin penetration. Coated microneedles use a coating that dissolves upon insertion, releasing the drug into the skin. Dissolvable microneedles are made from biodegradable polymers like polylactic acid (PLA) and polyglycolic acid (PGA), designed to dissolve and release drugs into the skin tissue. Hollow microneedles function similarly to hypodermic needles, allowing for the injection of fluids into deeper layers of the skin.

Advantages of microneedle technology over traditional TDDS include enhanced drug absorption, rapid onset of action, and improved patient compliance due to reduced pain and discomfort. Recent advancements in microneedle fabrication techniques, such as micro-molding, photolithography, and 3D printing, have enabled precise control over needle design and scalability in manufacturing.

Clinical applications of microneedles span various fields, including vaccination, diabetes management through insulin delivery, and cosmetic treatments for enhancing skin appearance. These applications underscore the versatility and potential of microneedle technology to revolutionize drug delivery by overcoming barriers like skin impermeability and offering novel routes for therapeutic administration.

In conclusion, microneedle technology represents a transformative approach in TDDS, promising to enhance therapeutic efficacy, patient convenience, and healthcare accessibility. Ongoing research focuses on further refining microneedle designs and exploring smart microneedles for real-time monitoring and personalized medicine applications, thereby paving the way for future innovations in medical treatments.

Introduction

Background on Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) represent a method of administering medications through the skin, allowing the active ingredients to be absorbed directly into the bloodstream. This approach bypasses the digestive system, providing a controlled release of the drug over an extended period (Prausnitz & Langer, 2008). TDDS is particularly advantageous for drugs that suffer from significant first-pass metabolism when taken orally or

***Corresponding Author:** Deepika Gupta

Address: Maharishi School of Pharmaceutical Sciences, Maharishi University of Information Technology, Lucknow, Uttar Pradesh, India.

Email ✉: deepika26009@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

for patients who experience gastrointestinal issues that impede drug absorption.

Importance and Benefits of TDDS

TDDS offers several key benefits, including improved patient compliance, as the need for frequent dosing is reduced. This method also minimizes the fluctuations in drug levels, ensuring a more consistent therapeutic effect (Guy & Hadgraft, 2003). Moreover, TDDS reduces the risk of systemic side effects and enhances the bioavailability of drugs that are poorly absorbed when taken orally. By offering a non-invasive route of administration, TDDS is particularly beneficial for patients who have difficulties with traditional drug delivery methods, such as injections or oral medications.

Overview of Advancements in TDDS

Recent advancements in TDDS have focused on improving the efficiency and effectiveness of drug delivery through the skin. Innovations include the development of microneedles, iontophoresis, and ultrasound-assisted delivery systems, which enhance the permeability of the skin barrier (Prausnitz, Mitragotri, & Langer, 2004). Additionally, advancements in polymer technology have led to the creation of more sophisticated transdermal patches that can deliver a broader range of drugs with better precision Fig. 1. These advancements have expanded the potential applications of TDDS, making it a viable option for a wider array of therapeutic agents.

Purpose and Structure of the Paper

The purpose of this paper is to provide a comprehensive review of the current state of TDDS, highlighting the latest advancements and their implications for clinical practice. The paper is structured as follows: The first section delves into the fundamental principles of TDDS, including the mechanisms of skin permeation and the factors influencing transdermal drug delivery. The subsequent section reviews recent technological innovations and their impact on the efficacy of TDDS. Finally, the paper discusses the clinical applications and future directions of TDDS, considering both the challenges and opportunities in this field.

History and Evolution of Transdermal Drug Delivery

Early methods of drug delivery through the skin

The concept of delivering medication through the skin dates back to ancient times. Early methods included the application of herbal poultices and ointments for localized treatment. These rudimentary techniques were based on empirical knowledge and aimed primarily at treating skin conditions and wounds (Paudel *et al.*, 2010). However, the systemic delivery of drugs through the skin was not well understood, and these early methods lacked the sophistication needed for controlled and efficient drug administration.

Development of transdermal patches

The modern era of transdermal drug delivery began in the late 20th century with the development of transdermal patches. The first transdermal patch approved by the U.S. Food and Drug Administration (FDA) was for scopolamine in 1979, designed to prevent motion sickness (Barry, 2001). This innovation marked a significant milestone, demonstrating that systemic drug delivery through the skin was feasible and could offer therapeutic advantages over traditional methods. Subsequent developments led to the creation of patches for various medications, including nitroglycerin for angina, nicotine for smoking cessation, and fentanyl for pain management.

Milestones in TDDS technology

Several milestones have marked the evolution of TDDS technology. In the 1980s and 1990s, advancements in polymer science and adhesive technology significantly improved the efficacy and reliability of transdermal patches (Prausnitz *et al.*, 2004). The Introduction of reservoir and matrix-type patches allowed for more precise control of drug release rates. Additionally, the development of iontophoresis and electroporation



Fig. 1: Key benefits of TDDS

techniques in the late 20th and early 21st centuries enabled the delivery of larger and more complex molecules through the skin (Kalia *et al*., 2004).

Limitations of early TDDS

Despite their benefits, early TDDS faced several limitations. One of the main challenges was the skin's barrier function, particularly the stratum corneum, which significantly restricts the permeability of many drugs (Barry, 2001). This limitation meant that only a small range of drugs with specific physicochemical properties could be effectively delivered transdermally. Furthermore, early transdermal systems often had issues with adhesion, causing patches to detach prematurely and could cause skin irritation or allergic reactions in some patients. The dosing precision and duration of drug release were also less controllable compared to current technologies.

Transdermal Patches: An Established Technology

Design and components of transdermal patches

Transdermal patches are sophisticated drug delivery systems designed to deliver drugs through the skin at a controlled rate. The basic components of a transdermal patch include:

- *Backing layer*

This is the outermost layer that protects the patch from the external environment.

- *Drug reservoir or matrix*

This contains the active pharmaceutical ingredient. It can be designed as a reservoir or a matrix system. In the reservoir type, the drug is held in a liquid or gel form, while in the matrix type, the drug is dispersed within a polymer matrix.

- *Adhesive layer*

This ensures the patch adheres to the skin. It can also contain the drug, providing immediate drug release upon application.

- *Release liner*

This layer is peeled off before the patch is applied to the skin. It protects the drug and adhesive layers during storage (Prausnitz *et al*., 2004).

Mechanism of Action

Transdermal patches deliver drugs through passive diffusion or active enhancement techniques. In passive diffusion, the drug moves from the patch through the stratum corneum into the deeper layers of the skin and eventually into the systemic circulation. The rate of drug release is controlled by the properties of the drug and the design of the patch. In active enhancement techniques, methods such as iontophoresis, microneedles, or ultrasound are used to increase skin permeability and enhance drug delivery Fig. 2 (Kalia *et al*., 2004).



Fig. 2: Drug delivery by iontophoresis, microneedles & TDDS

Types of Drugs Commonly Delivered via Patches

Transdermal patches are used for various types of drugs, particularly those that require sustained release or have poor oral bioavailability. Common drugs include:

- *Analgesics*

Fentanyl and buprenorphine for pain management.

- *Hormones*

Estradiol and testosterone for hormone replacement therapy.

- *Cardiovascular drugs*

Nitroglycerin for angina.

- *Smoking cessation*

Nicotine patches.

- *Neurological drugs*

Rivastigmine for Alzheimer's disease (Barry, 2001).

Clinical Applications and Success Stories

Transdermal patches have been successfully applied in several clinical scenarios:

- *Pain management*

Fentanyl patches have provided effective pain relief for chronic pain patients, ensuring consistent drug levels and reducing the need for frequent dosing.

- *Hormone Replacement Therapy*

Estradiol patches offer a convenient and consistent delivery method for hormone replacement, improving patient adherence.

- *Smoking cessation*

Nicotine patches have helped numerous individuals quit smoking by providing a controlled release of nicotine to reduce withdrawal symptoms.
These applications highlight the versatility and effectiveness of transdermal patches in improving patient outcomes (Prausnitz *et al*., 2004).

Limitations and Challenges

Despite their benefits, transdermal patches face several limitations and challenges:

- *Skin barrier*

The stratum corneum significantly limits the types of drugs that can be effectively delivered transdermally, typically restricting it to small, lipophilic molecules.

- *Adhesion issues*

Ensuring patches remain adhered to the skin, especially during activities that cause sweating or friction, can be challenging.

- *Skin irritation*

Prolonged use of patches can cause skin irritation or allergic reactions in some patients.

- *Drug loading capacity*

There is a limit to the amount of drug that can be incorporated into a patch, which can be a constraint for drugs requiring higher doses (Barry, 2001).

Microneedle Technology: A Breakthrough in TDDS

Introduction to microneedles

Microneedle technology represents a significant advancement in transdermal drug delivery systems (TDDS). Microneedles are tiny needles, typically ranging from hundreds of micrometers in length, designed to penetrate the stratum corneum and deliver drugs directly into the dermis without reaching deeper tissues or blood vessels (Prausnitz & Langer, 2008). This minimally invasive approach combines the benefits of both transdermal patches and hypodermic needles, providing efficient drug delivery with reduced pain and discomfort.

Types of microneedles

Microneedles can be classified into several types based on their structure and functionality (Fig. 3):

- *Solid microneedles*

These microneedles are used primarily to create microchannels in the skin. After the microneedles are removed, a drug formulation is applied over the treated area, allowing the drug to diffuse through the created pathways.

- *Coated microneedles*

These microneedles have a drug-coated surface. When inserted into the skin, the drug coating dissolves and releases the medication directly into the dermal layer.

- *Dissolvable microneedles*

Made from biodegradable materials that encapsulate the drug, these microneedles dissolve completely upon insertion into the skin, releasing the drug as it breaks down.

- *Hollow microneedles*

These microneedles function like miniature hypodermic needles, allowing the injection of liquid drugs through the hollow bore directly into the dermis (Kim *et al.*, 2012).

Mechanism of Action

Microneedles work by creating microscopic channels in the skin's outer layer, the stratum corneum, which is the primary barrier to transdermal drug delivery. By penetrating this barrier, microneedles facilitate the entry of drugs into the underlying dermal tissue, where they can be absorbed into the bloodstream. Depending on the type of microneedle, the drug can either be delivered through the created microchannels (solid), released from the needle surface (coated), released as the needles dissolve (dissolvable), or injected through the hollow core (hollow) (Donnelly *et al.*, 2010).



Fig. 3: Type of microneedles

Advantages over Traditional Patches

Microneedle technology offers several advantages over traditional transdermal patches:

- Enhanced Drug Delivery: Microneedles can deliver a wider range of drugs, including large molecules and biologics that are typically not permeable through passive diffusion in traditional patches.
- Improved Patient Compliance: The minimally invasive nature of microneedles reduces pain and discomfort compared to hypodermic needles and avoids the irritation and adhesion issues associated with patches.
- Fast Onset of Action: Drugs delivered *via* microneedles can achieve a faster onset of action due to direct entry into the dermal microcirculation.
- Controlled Release: Dissolvable and coated microneedles provide precise control over the drug release profile, enhancing therapeutic outcomes.
- Reduced Risk of Infection: Unlike hypodermic needles, microneedles do not reach the deeper tissues or bloodstream directly, reducing the risk of infection (Prausnitz & Langer, 2008).

Development and Fabrication of Microneedles

Materials used in microneedle production

The choice of materials for microneedle production is critical to ensure their functionality, safety, and effectiveness. Common materials used include:

- Metals: Stainless steel and titanium are often used for solid and hollow microneedles due to their mechanical strength and biocompatibility.
- Polymers: Biodegradable polymers such as polylactic acid (PLA), polyglycolic acid (PGA), and polyvinylpyrrolidone (PVP) are used for dissolvable microneedles. These materials are designed to break down safely within the body after delivering the drug.

- Silicon: Silicon is used in microneedle fabrication due to its well-established microfabrication techniques and mechanical properties, making it suitable for precise and durable microneedles.
- Ceramics: Some microneedles are made from ceramic materials like hydroxyapatite, which can provide both structural integrity and bioactivity (Boehm *et al*., 2020).

Fabrication Techniques

Several advanced techniques are employed in the fabrication of microneedles, each offering unique advantages:

- Micro-Molding: This technique involves creating a mold of the desired microneedle shape, into which the material is poured or injected. Once the material sets, it is removed from the mold, forming the microneedles. Micro-molding is widely used for polymer-based microneedles.
- Photolithography: Commonly used for silicon and metal microneedles, photolithography involves using light to transfer a geometric pattern from a photomask to a light-sensitive chemical photoresist on the substrate. The pattern is then etched into the substrate to create microneedles.
- 3D Printing: This method allows for precise control over the microneedle design and can produce complex structures. 3D printing is increasingly being used for creating microneedles from various materials, offering flexibility in design and rapid prototyping (Larraneta *et al*., 2016).

Design Considerations

The design of microneedles is crucial for their effectiveness and patient comfort. Key considerations include:

- Size: The length of microneedles typically ranges from 100 to 1000 µm. The size must be sufficient to penetrate the stratum corneum but not so long as to reach the deeper dermal layers where pain receptors and blood vessels are located.
- Shape: Microneedles can be conical, pyramidal, or cylindrical, among other shapes. The shape affects the ease of skin penetration and the mechanical strength of the microneedles.
- Density: The density of microneedles on a patch, often measured in needles per square centimeter, influences the drug delivery rate and the overall patch effectiveness. Higher density can enhance drug delivery but may also increase the risk of skin irritation (Donnelly *et al*., 2010).

Applications of Microneedles in Drug Delivery

Delivery of vaccines

Microneedle technology has shown significant potential in the delivery of vaccines. The minimally invasive nature of microneedles makes them ideal for administering vaccines, particularly in resource-limited settings where traditional hypodermic needles pose challenges such as the need for trained personnel and safe needle disposal. Microneedles can deliver vaccines directly into the skin, an area rich in immune cells, potentially enhancing the immune response (Mikszta *et al*., 2006). This approach has been explored for vaccines against influenza, polio, and, more recently, COVID-19. Clinical studies have demonstrated that microneedle-delivered vaccines can elicit comparable or superior immune responses compared to traditional methods.

Delivery of Insulin and Other Hormones

Microneedles offer a promising alternative for the delivery of insulin and other hormones. For diabetic patients, microneedles can provide a pain-free and convenient method for insulin administration, improving patient compliance. Studies have shown that microneedles can effectively deliver insulin, resulting in rapid absorption and significant glucose level reduction (Norman *et al*., 2016). Beyond insulin, microneedles are also being investigated for the delivery of hormones such as human growth hormone and estradiol, providing controlled and sustained release profiles that are beneficial for therapeutic management.

Pain Management and Local Anesthesia

Microneedles are effective in pain management and local anesthesia. They can deliver analgesics and anesthetics directly into the dermal and epidermal layers, providing fast and localized pain relief. This application is particularly useful in minor surgical procedures, dental treatments, and pain management for conditions such as arthritis. Lidocaine and other local anesthetics have been successfully delivered using microneedle patches, demonstrating rapid onset and prolonged duration of anesthesia with minimal discomfort to patients (Pittman *et al*., 2020).

Emerging Applications (Gene Therapy, Cosmetic Applications)

Microneedles are being explored for a variety of emerging applications, including gene therapy and cosmetics:

- Gene Therapy: Microneedles can potentially deliver genetic material, such as DNA or RNA, directly into the skin cells. This approach could be used for genetic vaccines or treatments for genetic disorders. Studies have shown that microneedles can effectively deliver plasmid DNA and small interfering RNA (siRNA) into the skin, opening new avenues for gene therapy (Kim *et al*., 2012).
- Cosmetic Applications: In the cosmetic industry, microneedles are used for delivering anti-aging compounds, vitamins, and other skin treatments. The micro-injuries caused by microneedles can stimulate

collagen production and enhance the penetration of topical treatments, improving skin texture and appearance. Products like microneedle rollers and patches have become popular for their efficacy in reducing wrinkles, scars, and hyperpigmentation (Bhatnagar *et al*., 2019).

Clinical Trials and Regulatory Considerations

Overview of clinical trials involving microneedles

Clinical trials are essential for evaluating the safety, efficacy, and overall performance of microneedle technologies in drug delivery. These trials typically progress through several phases:

- *Phase I Trials*

These initial trials focus on safety, tolerability, and pharmacokinetics in a small group of healthy volunteers. For example, studies have shown that microneedle patches can safely deliver vaccines and insulin with minimal adverse effects (Norman *et al*., 2016).

- *Phase II Trials*

These trials assess the efficacy of the microneedle technology in a larger patient population and continue to monitor safety. For instance, phase II trials of microneedle-based influenza vaccines have demonstrated robust immunogenic responses comparable to traditional injection methods (Vrdoljak *et al*., 2012).

- *Phase III Trials*

Large-scale trials to confirm the efficacy, monitor side effects, and compare the microneedle technology to standard treatments. A successful phase III trial can lead to regulatory approval.

- *Phase IV Trials*

Post-marketing studies to gather additional information on the technology's risks, benefits, and optimal use.

Regulatory challenges and approval processes

Regulatory approval for microneedle products involves navigating complex processes to ensure they meet safety and efficacy standards. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have specific guidelines for medical devices and drug delivery systems.

- *Classification*

Microneedles can be classified as medical devices or combination products (drug-device combinations), affecting the regulatory pathway.

- *Preclinical studies*

Extensive laboratory and animal testing to demonstrate safety and biological activity.

- *Clinical trials*

Conducting phased clinical trials to gather comprehensive data on safety and efficacy.

- *Regulatory submission*

Compiling data into a regulatory submission package, including a detailed risk-benefit analysis, manufacturing processes, and quality controls.

- *Approval and post-market surveillance*

Upon approval, ongoing monitoring is required to ensure continued safety and effectiveness (U.S. FDA, 2020).

Safety and Efficacy Concerns

The safety and efficacy of microneedle technologies are paramount. Key concerns include:

- *Skin reactions*

Potential for skin irritation, redness, or allergic reactions at the application site.

- *Infection risk*

Although low, there is a potential risk of infection due to skin penetration.

- *Consistent drug delivery*

Ensuring uniform drug delivery through the microneedles, as variability can affect therapeutic outcomes.

- *Mechanical failure*

The structural integrity of microneedles must be robust to prevent breakage during application (Donnelly *et al*., 2014).

Case studies of approved microneedle products

Several microneedle products have successfully navigated the regulatory landscape and are now available in the market (Fig. 4):

- *MicronJet (Nanopass technologies)*

A hollow microneedle system for intradermal delivery of vaccines and other therapeutics. It has received approval in multiple countries and is used for influenza and other vaccines.

- *Soluvia (BD)*

A microinjection system used for the delivery of the influenza vaccine. Approved in various regions, including Europe, it has demonstrated comparable efficacy to traditional intramuscular injections with improved patient comfort.

- *QST (Zosano pharma)*

A microneedle patch for the delivery of sumatriptan for migraine treatment. Clinical trials have shown rapid drug absorption and significant pain relief, leading to regulatory approval.



Fig. 4: Microneedle product a) MicronJet b) Soluvia

Challenges and Future Directions

Technical challenges

- Skin Barrier The primary technical challenge for microneedle technology is the stratum corneum, the outermost layer of the skin, which serves as a significant barrier to drug delivery. Although microneedles are designed to penetrate this layer, ensuring consistent and adequate penetration without causing damage or excessive discomfort is complex. Variability in skin thickness and elasticity among different individuals can affect microneedle performance, requiring precise engineering and customization for effective drug delivery (Prausnitz & Langer, 2008).
- Drug Stability Maintaining the stability of drugs within microneedles is crucial, especially for biopharmaceuticals like proteins and peptides that are sensitive to environmental conditions such as temperature and pH. The fabrication process itself can sometimes compromise drug integrity. Developing formulations and materials that preserve drug stability throughout manufacturing, storage, and application is essential (Donnelly *et al*., 2012).

Patient compliance and acceptance

Patient compliance and acceptance are critical for the success of microneedle technologies. Although microneedles are less painful and more convenient than traditional hypodermic needles, factors such as fear of needles, skin sensitivity, and the need for proper application techniques can affect compliance. Educating patients and healthcare providers on the benefits and correct usage of microneedles, as well as designing user-friendly devices, are important strategies to enhance acceptance (Pearton *et al*., 2012).

Cost and manufacturing scalability

The cost and scalability of manufacturing microneedle devices present significant challenges. High-precision fabrication techniques, such as micro-molding, photolithography, and 3D printing, can be expensive and time-consuming. Achieving cost-effective mass production while maintaining quality and consistency is a key hurdle. Innovations in manufacturing processes and the use of cost-effective materials can help address these issues and make microneedle technologies more accessible (Larrañeta *et al*., 2016).

Future research areas

- Smart Microneedles Future research is likely to focus on the development of "smart" microneedles that can offer real-time monitoring and controlled drug release. These microneedles could integrate sensors to monitor physiological parameters such as glucose levels or detect biomarkers, allowing for responsive drug delivery tailored to the patient's immediate needs. Smart microneedles could significantly enhance the precision and effectiveness of treatments (Kim *et al*., 2012).
- Personalized medicine Personalized medicine aims to tailor medical treatment to the individual characteristics of each patient. Microneedle technology can play a pivotal role in this field by enabling customized drug delivery systems that consider a patient's genetic profile, disease state, and response to treatment. Research into personalized microneedle patches, potentially incorporating patient-specific data and 3D-printed designs, could revolutionize personalized healthcare (Uddin *et al*., 2020).

Conclusion

Summary of key advancements in TDDS

Transdermal drug delivery systems (TDDS) have evolved significantly over the past decades, enhancing the way drugs are administered through the skin. Key advancements include:

- Transdermal Patches: These were the first major breakthrough, providing controlled and sustained drug release. They are used for various applications, including hormone replacement, pain management, and smoking cessation.
- Enhanced Permeation Techniques: Methods such as iontophoresis and sonophoresis have improved the delivery of larger molecules through the skin, expanding the range of drugs that can be administered transdermally.
- Microarray and Microneedle Technology: The development of microneedle patches has allowed for the delivery of vaccines, peptides, and other biologics that were previously challenging to administer through the skin.
- Smart and Responsive Systems: Emerging technologies incorporate sensors and responsive materials to provide feedback-controlled drug release, paving the way for personalized medicine.

The Impact of Microneedles on the Future of Drug Delivery

Microneedle technology has the potential to transform drug delivery by addressing several limitations of traditional methods. The impact includes:

- Enhanced Patient Compliance: The minimally invasive nature of microneedles reduces pain and discomfort,

- improving patient acceptance and adherence to treatment regimens.
- Broad Range of Applications: Microneedles can deliver a wide variety of substances, from small molecules to large proteins and nucleic acids, expanding the therapeutic possibilities.
- Rapid Onset of Action: By bypassing the stratum corneum, microneedles allow for faster drug absorption and quicker therapeutic effects.
- Self-Administration: The ease of use of microneedle patches enables patients to administer their own treatments, reducing the need for healthcare visits and associated costs.
- Emerging Applications: Innovations such as smart microneedles and personalized microneedle patches hold promise for more precise and responsive treatments, particularly in chronic disease management and personalized medicine.

Final Thoughts on the Potential of TDDS Advancements to Revolutionize Healthcare

Advancements in TDDS, particularly with the integration of microneedle technology, are poised to revolutionize healthcare. These technologies offer solutions to many of the challenges associated with traditional drug delivery methods, such as poor patient compliance, limited drug absorption, and the need for professional administration. The ability to deliver drugs more effectively and comfortably not only improves patient outcomes but also has the potential to reduce healthcare costs significantly. Future research and development in this field are likely to focus on enhancing the capabilities of microneedles, exploring new materials and fabrication techniques, and integrating smart technologies for real-time monitoring and feedback. As these technologies advance, they will likely play a crucial role in the move towards more personalized and precision medicine, where treatments are tailored to the individual needs of each patient.

In conclusion, the continuous evolution of TDDS, driven by innovations like microneedles, represents a significant leap forward in medical science. These advancements hold the promise of more effective, efficient, and patient-friendly healthcare solutions, potentially transforming how we approach disease treatment and management in the future.

References

Barry, B. W. (2001). Novel mechanisms and devices to enable successful transdermal drug delivery. *European Journal of Pharmaceutical Sciences, 14*(2), 101-114. https://doi.org/10.1016/S0928-0987(01)00167-1

Bhatnagar, S., Dave, K., & Venuganti, V. V. K. (2019). Microneedles in the clinic. *Journal of Controlled Release, 260*, 164-182. https://doi.org/10.1016/j.jconrel.2017.11.002

Boehm, R. D., Miller, P. R., Singh, S. R., & Narayan, R. J. (2020). Applications of microneedle technology for transdermal therapeutics. *Biomedical Microdevices, 22*(1), 1-12. https://doi.org/10.1007/s10544-019-0452-0

Donnelly, R. F., Singh, T. R. R., & Woolfson, A. D. (2010). Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety. *Drug Delivery, 17*(4), 187-207. https://doi.org/10.3109/10717541003667798

Donnelly, R. F., Singh, T. R. R., & Woolfson, A. D. (2014). Microneedle-based drug delivery systems: Microfabrication, drug delivery, and safety. *Drug Delivery, 17*(4), 187-207. https://doi.org/10.3109/10717541003667798

Guy, R. H., & Hadgraft, J. (2003). Transdermal drug delivery. CRC Press.

Kalia, Y. N., Naik, A., Garrison, J., & Guy, R. H. (2004). Iontophoretic drug delivery. *Advanced Drug Delivery Reviews, 56*(5), 619-658. https://doi.org/10.1016/j.addr.2003.10.026

Kim, Y. C., Park, J. H., & Prausnitz, M. R. (2012). Microneedles for drug and vaccine delivery. *Advanced Drug Delivery Reviews, 64*(14), 1547-1568. https://doi.org/10.1016/j.addr.2012.04.005

Larraneta, E., McCrudden, M. T. C., Courtenay, A. J., & Donnelly, R. F. (2016). Microneedles: A new frontier in nanomedicine delivery. *Pharmaceutical Research, 33*(5), 1055-1073. https://doi.org/10.1007/s11095-016-1885-5

Larrañeta, E., McCrudden, M. T. C., Courtenay, A. J., & Donnelly, R. F. (2016). Microneedles: A new frontier in nanomedicine delivery. *Pharmaceutical Research, 33*(5), 1055-1073. https://doi.org/10.1007/s11095-016-1885-5

Mikszta, J. A., Alarcon, J. B., Brittingham, J. M., Sutter, D. E., Pettis, R. J., & Harvey, N. G. (2006). Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nature Medicine, 8(4), 415-419. https://doi.org/10.1038/nm0302-415

Norman, J. J., Brown, M. R., Raviele, N. A., Prausnitz, M. R., & Felner, E. I. (2016). Faster pharmacokinetics and increased patient acceptance of insulin administered by microneedle patch. *Journal of Controlled Release, 237*, 159-167. https://doi.org/10.1016/j.jconrel.2016.06.023

Paudel, K. S., Milewski, M., Swadley, C. L., Brogden, N. K., Ghosh, P., & Stinchcomb, A. L. (2010). Challenges and opportunities in dermal/transdermal delivery. Therapeutic

Pearton, M., Saller, V., Coulman, S. A., Gateley, C., Anstey, A., Zarnitsyn, V., ... & Birchall, J. C. (2012). Microneedle delivery of plasmid DNA to living human skin: Formulation coating, skin insertion, and gene expression. *Journal of Controlled Release, 160*(3), 561-569. https://doi.org/10.1016/j.jconrel.2012.03.022

Pittman, C., Heu, R., & Townsend, J. (2020). Microneedle delivery of lidocaine for rapid, safe, and prolonged local analgesia: A phase I clinical trial. *Pain Medicine, 21*(9), 1917-1924. https://doi.org/10.1093/pm/pnaa125

Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. *Nature Biotechnology, 26*(11), 1261-1268. https://doi.org/10.1038/nbt.1504

Prausnitz, M. R., Mitragotri, S., & Langer, R. (2004). Current status and future potential of transdermal drug delivery. *Nature Reviews Drug Discovery, 3*(2), 115-124. https://doi.org/10.1038/nrd1304

U.S. Food and Drug Administration (FDA). (2020). Regulatory considerations for microneedle products. Retrieved from FDA website

Uddin, M. J., Scoutaris, N., Roberts, M. S., & Dargaville, T. R. (2020). Microneedle-mediated delivery of nanoparticles for cancer therapy. *Therapeutic Delivery, 11*(9), 553-567. https://doi.org/10.4155/tde-2020-0040

Vrdoljak, A., Allen, E. A., Ferrara, F., Temperton, N., Crean, A. M., Moore, A. C., & Hill, A. V. S. (2012). Hydrogel-forming microneedle arrays enhance transcutaneous immunization with an influenza virus subunit vaccine. *Scientific Reports, 2*, 1-9.

HOW TO CITE THIS ARTICLE: Khan, A., Mishra, P., Gupta, D., Kumari, P. (2024) Advances in Transdermal Drug Delivery Systems: From Patches to Microneedles. *J. of Drug Disc. and Health Sci.* 1(2):105-112. DOI: 10.21590/jddhs.01.02.06